戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 oroidal thickness [SFCT], phakic status, and best-corrected visual acuity.
2 d Early Treatment Diabetic Retinopathy Study best-corrected visual acuity.
3 jections (IVT), retinal detachment rate, and best-corrected visual acuity.
4        A significant difference was found in best-corrected visual acuity (0.01 logarithm of the mini
5 set (aged </=3 years) visual loss (mean [SD] best-corrected visual acuity, +0.95 [0.34] logMAR [20/18
6 r incidence of 15-letter or more decrease in best-corrected visual acuity (14% vs. 31%), and reduced
7 tained: subjective and objective refraction, best-corrected visual acuity, accommodation, contrast se
8                                        Final best-corrected visual acuity after chronic central serou
9                                              Best-corrected visual acuity after Descemet's stripping
10 ary outcome measures were the mean change in best corrected visual acuity and adverse events.
11                                              Best-corrected visual acuity and central macular thickne
12                             At 2 years, mean best-corrected visual acuity and central retinal thickne
13 primary outcomes included the mean change in best-corrected visual acuity and central retinal thickne
14                                              Best-corrected visual acuity and CFT were examined from
15 ure at 6 days, rate of re-epithelialization, best-corrected visual acuity and infiltrate and/or scar
16                                    Monocular best-corrected visual acuity and reading acuity together
17        They were analyzed according to final best-corrected visual acuity and retinal morphological p
18 ariate analysis, after adjusting for initial best-corrected visual acuity and the antimicrobial treat
19 ata collected included patient demographics, best-corrected visual acuity, and OCT features of vitreo
20 egression analyses adjusted for age, gender, best-corrected visual acuity, and test duration showed t
21 tening complications), nonpersistent loss of best-corrected visual acuity, and transient hypotony (re
22 d on assessment of new inflammatory lesions, best corrected visual acuity, anterior chamber cell grad
23 rameters were evaluated: severity of injury, best corrected visual acuity at admission and last follo
24 tive vitreous hemorrhage, and mean change in best-corrected visual acuity at 12 months.
25 e primary outcome was defined as a change in best-corrected visual acuity at 52 weeks with a linear m
26                                              Best-corrected visual acuity at baseline was 0.5+/-0.1 l
27                                              Best-corrected visual acuity at fluid resolution was not
28  vs. 1.7%; P = 0.03) and significantly worse best-corrected visual acuity at the 12-month follow-up (
29              The primary outcome measure was best-corrected visual acuity at the final visit.
30  -0.17, -0.04; beta: -0.04; P = .003), worse best-corrected visual acuity (B: 0.64; 95% CI: 0.38, 0.9
31 imary outcome measure was change in the mean best corrected visual acuity (BCVA) after nine months, s
32                                              Best corrected visual acuity (BCVA) and stereoacuity (St
33 ances of the applied IOP-lowering drugs, the best corrected visual acuity (BCVA) and the mean deviati
34                                              Best corrected visual acuity (BCVA) at 6 weeks follow-up
35                                Mean distance Best corrected visual acuity (BCVA) at initial presentat
36       The progression of non-RRD resulted in best corrected visual acuity (BCVA) decrease from 0.8 to
37 er in the younger age group (p-value 0.209), best corrected visual acuity (BCVA) improved significant
38 analysis showed a significant improvement of best corrected visual acuity (BCVA) in the treated eye o
39                  Intraocular pressure (IOP), best corrected visual acuity (BCVA) logMAR and number of
40 atients with eyelid injuries showed a median best corrected visual acuity (BCVA) of logMAR 0.0.
41 d with regard to symptoms, refractive error, best corrected visual acuity (BCVA) of logMAR, binocular
42    The primary outcome measure was change in best corrected visual acuity (BCVA) over time.
43                                 Preoperative best corrected visual acuity (BCVA) showed and improveme
44              Ophthalmic examination included best corrected visual acuity (BCVA) testing and multimod
45                                              Best corrected visual acuity (BCVA), central retinal thi
46 ration of uveitis, severity of inflammation, best corrected visual acuity (BCVA), cystoid macular ede
47                Preoperative characteristics, best corrected visual acuity (BCVA), mean absolute spher
48 in outcomes were mean pre- and postoperative best corrected visual acuity (BCVA), postoperative astig
49  preoperative, early postoperative and final best corrected visual acuity (BCVA), rate of complicatio
50 ove both central macular thickness (CMT) and best corrected visual acuity (BCVA).
51 (CMT on SD-OCT; mum) and the visual outcome (best corrected visual acuity (BCVA); logMAR), as follows
52 y associated with capsule complications were best-corrected visual acuity (BCVA) <=0.1 (decimal, adju
53 icantly lower FVA and VR QoL included, lower best-corrected visual acuity (BCVA) (P < .0001 for both
54 jects were >/=65 years, had wet AMD, and had best-corrected visual acuity (BCVA) 10/200 to 20/80 in t
55 owing: 5-letter or fewer gain from baseline, best-corrected visual acuity (BCVA) 20/40 or worse, and
56                                              Best-corrected visual acuity (BCVA) 6 months after surge
57 ibercept in a q8-week regimen with regard to best-corrected visual acuity (BCVA) and brolucizumab ach
58 cy end point of the study was mean change in best-corrected visual acuity (BCVA) and central foveal t
59                                              Best-corrected visual acuity (BCVA) and central retinal
60      To investigate the relationship between best-corrected visual acuity (BCVA) and central retinal
61            Mean (and mean average) change in best-corrected visual acuity (BCVA) and central subfield
62 EGF injections and improvement from baseline best-corrected visual acuity (BCVA) and central subfield
63  association of these features with baseline best-corrected visual acuity (BCVA) and change in BCVA a
64 re assessed, as were the predictors of final best-corrected visual acuity (BCVA) and change in BCVA.
65 on was matched to investigate differences in best-corrected visual acuity (BCVA) and compared the sur
66 y (QUS) to measure vitreous echodensity, and best-corrected visual acuity (BCVA) and contrast sensiti
67  Questionnaire (VFQ-39) and were tested with best-corrected visual acuity (BCVA) and CSF measurements
68                                              Best-corrected visual acuity (BCVA) and CST were measure
69 ithm of minimum angle of resolution (logMAR) best-corrected visual acuity (BCVA) and evolution of mor
70                                 Poor initial best-corrected visual acuity (BCVA) and foveal and optic
71 ubjects underwent eye examinations including best-corrected visual acuity (BCVA) and Heidelberg Spect
72                 Allocation was stratified by best-corrected visual acuity (BCVA) and hospital.
73              Secondary outcome measures were best-corrected visual acuity (BCVA) and neovascularizati
74 ospective comparative-effectiveness study of best-corrected visual acuity (BCVA) and refractive error
75 nt ophthalmic examination with assessment of best-corrected visual acuity (BCVA) and retinal imaging,
76                                              Best-corrected visual acuity (BCVA) and spectral domain
77 iation maculopathy confirmed by a decline in best-corrected visual acuity (BCVA) and spectral-domain
78        The main outcomes measured were final best-corrected visual acuity (BCVA) and surgical complic
79     To estimate the yearly rate of change of best-corrected visual acuity (BCVA) and the risk of loss
80 ma (group D) presented with light perception best-corrected visual acuity (BCVA) and tractional retin
81 aseline and annual eye examinations included best-corrected visual acuity (BCVA) assessments, slit-la
82 categorized into 3 groups based on change in best-corrected visual acuity (BCVA) at 3 months (logMAR
83                      The primary outcome was best-corrected visual acuity (BCVA) at 6 months follow-u
84               The main outcome measures were best-corrected visual acuity (BCVA) at final follow-up v
85 -domain optical coherence tomography and the best-corrected visual acuity (BCVA) at six months.
86  primary outcome was change in amblyopic eye best-corrected visual acuity (BCVA) at the 2-week visit.
87 rimary outcome measurement was the change in best-corrected visual acuity (BCVA) at the end of the fo
88 ogy of SJS/TEN, age at treatment milestones, best-corrected visual acuity (BCVA) at treatment milesto
89                                          The best-corrected visual acuity (BCVA) before and after sur
90 5 mum, and visual impairment from DME with a best-corrected visual acuity (BCVA) between 24 letters a
91  baseline retinal morphologic parameters and best-corrected visual acuity (BCVA) change (structure-fu
92                          Primary measure was best-corrected visual acuity (BCVA) change from baseline
93 : 5 letters at a 1-sided alpha level 0.1) in best-corrected visual acuity (BCVA) change from baseline
94                                         Mean best-corrected visual acuity (BCVA) change from baseline
95  to first recurrence, number of recurrences, best-corrected visual acuity (BCVA) change from baseline
96 atients with prior anti-VEGF treatment, mean best-corrected visual acuity (BCVA) changes from baselin
97                                              Best-corrected visual acuity (BCVA) data, retinal imagin
98  3 and month 6 after treatment, and a better best-corrected visual acuity (BCVA) during the first thr
99 ons, including measurement of presenting and best-corrected visual acuity (BCVA) for distance using t
100  [95% confidence interval], P value) gain in best-corrected visual acuity (BCVA) from baseline at Mon
101   The primary endpoint is the mean change in best-corrected visual acuity (BCVA) from baseline to 24
102    Main outcomes were mean average change in best-corrected visual acuity (BCVA) from baseline to mon
103 ome was improvement of 15 or more letters in best-corrected visual acuity (BCVA) from baseline.
104 acuity with presenting correction (APC), and best-corrected visual acuity (BCVA) from each eye.
105                                         Mean best-corrected visual acuity (BCVA) gains in the 2q4, 2q
106                                              Best-corrected visual acuity (BCVA) improved by -0.89 lo
107                            Mean preoperative best-corrected visual acuity (BCVA) improved from 0.53+/
108                              Two weeks later best-corrected visual acuity (BCVA) improved up to 20/25
109 cataract surgery and the patients (%) with a best-corrected visual acuity (BCVA) improvement of >/=15
110                                          The best-corrected visual acuity (BCVA) improvement was 0.16
111 s to be shown using a margin of 5 letters in best-corrected visual acuity (BCVA) improvement.
112 retinal inner layers (DRIL) is predictive of best-corrected visual acuity (BCVA) in retinal vein occl
113 ntage of eyes with improvement from baseline best-corrected visual acuity (BCVA) letter score >/=15 a
114                                         Mean best-corrected visual acuity (BCVA) letter score change,
115 oroidal neovascularization in either eye and best-corrected visual acuity (BCVA) letter score of 49 l
116 njections, then retreatment guided by either best-corrected visual acuity (BCVA) loss (Group I) or BC
117 mplete ophthalmologic examination, including best-corrected visual acuity (BCVA) measurement on ETDRS
118       The primary outcome was 1-year gain in best-corrected visual acuity (BCVA) of >/=15 letters.
119                                      All had best-corrected visual acuity (BCVA) of 20/20, no dry eye
120 lusion criteria included presence of VMA and best-corrected visual acuity (BCVA) of 20/32 or worse in
121 o age-related macular degeneration (AMD) and best-corrected visual acuity (BCVA) of 20/80 to 20/800.
122             Patients were required to have a best-corrected visual acuity (BCVA) of 5 or more Early T
123 (range, 239-727 mum) and a mean preinjection best-corrected visual acuity (BCVA) of 63 approximated E
124                 After DMEK surgery, the mean best-corrected visual acuity (BCVA) ranged from 20/21 to
125 nical visit after the loading phase, OCT and best-corrected visual acuity (BCVA) testing were perform
126 .7 +/- 16.4 years (range 14-66) and the mean best-corrected visual acuity (BCVA) was 0.1 +/- 0.2 logM
127 ry high-volume cataract surgeons; the median best-corrected visual acuity (BCVA) was 0.5 (decimal) co
128                            Mean preoperative best-corrected visual acuity (BCVA) was 1.11+/-0.59 loga
129                        The mean preoperative best-corrected visual acuity (BCVA) was 1.39+/-0.64 loga
130 nimum angle of resolution (logMAR) (Snellen) best-corrected visual acuity (BCVA) was 1.81+/-0.56 (20/
131                            Mean preoperative best-corrected visual acuity (BCVA) was 20/2000 (2 logar
132                                       Median best-corrected visual acuity (BCVA) was 20/30 at present
133 ce between the median preoperative and final best-corrected visual acuity (BCVA) was assessed and the
134                                     Baseline best-corrected visual acuity (BCVA) was better in LCS co
135                                     Baseline best-corrected visual acuity (BCVA) was between 0.3 and
136                                              Best-corrected visual acuity (BCVA) was compared between
137                    Mean change from baseline best-corrected visual acuity (BCVA) was determined at we
138                                              Best-corrected visual acuity (BCVA) was measured 30 to 9
139 by time-domain optical coherence tomography, best-corrected visual acuity (BCVA) was measured by Earl
140 , and spectral-domain OCT were conducted and best-corrected visual acuity (BCVA) was obtained at base
141                                              Best-corrected visual acuity (BCVA) was recorded preoper
142                                         Mean best-corrected visual acuity (BCVA) was stable; 3 implan
143                  Lesion size assessments and best-corrected visual acuity (BCVA) were conducted at sc
144           Presenting visual acuity (PVA) and best-corrected visual acuity (BCVA) were measured using
145          Follow-up OCT imaging and monocular best-corrected visual acuity (BCVA) were performed for t
146                           The mean change in best-corrected visual acuity (BCVA) with IVT-AFL from ba
147                       Safety end points were best-corrected visual acuity (BCVA), adverse events (AEs
148                                 Furthermore, best-corrected visual acuity (BCVA), age, and retinal pi
149                                          The best-corrected visual acuity (BCVA), Amsler test, M-char
150 al uncorrected visual acuity (UCVA), decimal best-corrected visual acuity (BCVA), and average keratom
151                    Intraocular inflammation, best-corrected visual acuity (BCVA), and corticosteroid-
152 uded >=20% improvement and resolution of ME, best-corrected visual acuity (BCVA), and intraocular pre
153 omain optical coherence tomography (SD-OCT), best-corrected visual acuity (BCVA), and microperimetry.
154      Evaluations at each time point included best-corrected visual acuity (BCVA), anterior and poster
155 ements included endothelial cell loss (ECL), best-corrected visual acuity (BCVA), central corneal thi
156 moglobin A1c (HbA1c), body mass index (BMI), best-corrected visual acuity (BCVA), central subfield th
157    This study assessed relationships between best-corrected visual acuity (BCVA), central subfield th
158 mologic examinations including assessment of best-corrected visual acuity (BCVA), contrast sensitivit
159                   Main outcome measures were best-corrected visual acuity (BCVA), endothelial cell de
160 The main outcome measures were postoperative best-corrected visual acuity (BCVA), endothelial cell de
161                   Main outcome measures were best-corrected visual acuity (BCVA), endothelial cell de
162                   Main outcome measures were best-corrected visual acuity (BCVA), endothelial cell de
163   Review of charts and photographs comprised best-corrected visual acuity (BCVA), foveal center field
164                                              Best-corrected visual acuity (BCVA), foveal thickness, t
165 MainOutcome Measures: Clinical presentation, best-corrected visual acuity (BCVA), fundus abnormalitie
166 subdivided into classic stages and underwent best-corrected visual acuity (BCVA), fundus autofluoresc
167 ar hole (FTMH), mean change from baseline in best-corrected visual acuity (BCVA), incidence of vitrec
168                                    Change of best-corrected visual acuity (BCVA), intraocular pressur
169 ular comorbidities, ocular surgical history, best-corrected visual acuity (BCVA), intraocular pressur
170 ation, distance of GA lesion from the fovea, best-corrected visual acuity (BCVA), low-luminance BCVA,
171     Measurements of visual function included best-corrected visual acuity (BCVA), low-luminance visua
172  outcome measures were the rate of change in best-corrected visual acuity (BCVA), low-luminance visua
173                                              Best-corrected visual acuity (BCVA), macular sensitivity
174                               Change in mean best-corrected visual acuity (BCVA), mean central retina
175                                              Best-corrected visual acuity (BCVA), moderate visual los
176 demographics, preoperative and postoperative best-corrected visual acuity (BCVA), nuclear density, ex
177              Secondary outcome measures were best-corrected visual acuity (BCVA), number of antiglauc
178                    Outcome measurements were best-corrected visual acuity (BCVA), refractive astigmat
179                               Improvement in best-corrected visual acuity (BCVA), resolution of subre
180            The parameters evaluated were the best-corrected visual acuity (BCVA), Schirmer test, tear
181 ratory efficacy measures included changes in best-corrected visual acuity (BCVA), static perimetry ce
182                                              Best-corrected visual acuity (BCVA), tear osmolarity, th
183 was assessed and correlated to the degree of best-corrected visual acuity (BCVA).
184 erative complications, device retention, and best-corrected visual acuity (BCVA).
185 radiation retinopathy, optic neuropathy, and best-corrected visual acuity (BCVA).
186                    Ocular surface stability, best-corrected visual acuity (BCVA).
187 al severity scale, vascular clock hours, and best-corrected visual acuity (BCVA).
188 OCTA contributed significantly to diminished best-corrected visual acuity (BCVA).
189          The objective tests were scores for best-corrected visual acuity (BCVA); using the LogMAR sc
190             All groups demonstrated improved best-corrected visual acuity (BCVA; average, 0.46 logari
191 near and distant activities subscale scores, best-corrected visual acuity (BCVA; Early Treatment Diab
192    Eyes with predominantly classic CNV (mean best-corrected visual acuity [BCVA], 48.2 letters at bas
193           Main outcome parameters (survival, best-corrected visual acuity [BCVA], central endothelial
194 arameters, postvitrectomy complications, and best-corrected visual acuities (BCVAs) were identified.
195  detachment (SRD) with single PDT, change in best-corrected visual acuities (BCVAs), and recurrence r
196                               Black on White Best Corrected Visual Acuity (BW-BCVA), White on Black B
197               Main outcome measures included best-corrected visual acuity, central retinal thickness,
198 cuity response (mean change from baseline in best-corrected visual acuity [CFB BCVA]; categorized imp
199                      The primary outcome was best-corrected visual acuity change (DeltaBCVA, logarith
200                                              Best-corrected visual acuity changed by -0.2 letters in
201 s underwent a baseline examination including best-corrected visual acuity, color photos, optical cohe
202 mologic examinations included cover testing, best corrected visual acuity, cycloplegic objective refr
203                                     The mean best-corrected visual acuity declined by 2 lines post-PE
204                                              Best-corrected visual acuity decreased from 20/25 to 20/
205 duration of diabetes, source of referral and best-corrected visual acuity, diabetic retinopathy statu
206                                     Baseline best-corrected visual acuity differed between these grou
207 modified intention-to-treat population (mean best corrected visual acuity difference 3.9 letters [95%
208                                      Because best-corrected visual acuity does not correspond directl
209 ere was a significant increase (P < .001) in best-corrected visual acuity from a letter score of 63.3
210       There was a significant improvement in best-corrected visual acuity from a mean of 0.65 LogMAR
211 endpoints were the change in mean and median best-corrected visual acuity from baseline at years 1 an
212                       The eye with the worst best-corrected visual acuity from each patient was selec
213  symptoms and the results of ophthalmoscopy, best-corrected visual acuity, full-field electroretinogr
214                                              Best-corrected visual acuity, fundus photographs, and sp
215 horoidal thickness) for functional response (best-corrected visual acuity gain >/=2 lines) were asses
216                                     The mean best-corrected visual acuity gain from baseline to week
217 met its main objective, demonstrating a mean best-corrected visual acuity gain of 8.3 letters (mean 6
218                                              Best-corrected visual acuity gains achieved during VISTA
219 A subgroup of PRN patients were analyzed for best-corrected visual acuity gains at 24 months.
220                                         Mean best-corrected visual acuity gains from baseline with Rq
221                     In seven cases, the mean best-corrected visual acuity improved after foveal reatt
222 n unaided visual acuity was 6/12 (20/40) and best-corrected visual acuity improved from 6/20 (20/63)
223    Following the first implantation, average best-corrected visual acuity improved significantly from
224                                  Significant best-corrected visual acuity improvement was associated
225                                              Best-corrected visual acuity in logarithm of minimum ang
226  million people in the United States had VI (best-corrected visual acuity in the better-seeing eye),
227  Primary outcome was change from baseline in best-corrected visual acuity in uveitic eyes (5 letters
228 up, including preoperative and postoperative best-corrected visual acuity, incidence of macular edema
229                                              Best-corrected visual acuity, Indian Vision Function Que
230                   All patients had preserved best-corrected visual acuity into adulthood, with a mean
231  an exhaustive ophthalmological examination (best-corrected visual acuity, intraocular pressure, biom
232                      Patients with decreased best corrected visual acuity, Khodadoust line, and anter
233                                              Best-corrected visual acuity letter score gain of 15 let
234                                 Median BCVA (best-corrected visual acuity, logMAR) was 0.1 in the MFS
235               The main outcome measures were best-corrected visual acuity, long-term ocular sequelae,
236            risk factors associated with SVI (best-corrected visual acuity &lt;20/200) and vision-threate
237                                          His best corrected visual acuity markedly improved from 20/5
238                           Postoperative mean best-corrected visual acuity measured 0.14+/-0.26 logari
239                                       Median best-corrected visual acuity measured 20/63 (range, 20/2
240        Every 4 weeks, participants underwent best-corrected visual acuity measurement, fundus examina
241 als aged 3 years or older with, in each eye, best corrected visual acuity of 20/60 or worse, or visua
242 nts with open globe injuries showed a median best corrected visual acuity of logMAR 1.5 at admission,
243 t had experienced at least 1 RD, achieving a best-corrected visual acuity of >/=20/40 compared to 53%
244                                        Final best-corrected visual acuity of >20/200 was achieved in
245 and a half times more likely to have a final best-corrected visual acuity of <20/60 compared to those
246 ision, with the exception of 3 patients with best-corrected visual acuity of 0.8 (Snellen).
247  from 11 to 89 years of age, with a baseline best-corrected visual acuity of 2.3 to -0.2 logarithm of
248 among 12 patients with visual impairment and best-corrected visual acuity of 20/200 or worse in their
249 last follow-up, 6 of 19 patients (31.6%) had best-corrected visual acuity of 20/400 or better.
250 patient age was 34.2 (14.7) years, mean (SD) best-corrected visual acuity of all eyes was 47.8 (16.9)
251 nd 11 eyes with low MS (<6 dB) but very good best-corrected visual acuity of at least 72 Early Treatm
252                                Postoperative best-corrected visual acuity of the study group was wors
253 at onset, medical history, initial symptoms, best-corrected visual acuity, ophthalmoscopy, fundus pho
254 of pattern-reversal visual evoked potential, best-corrected visual acuity, optic nerve appearance, vi
255  months; >98% of all subjects achieved 20/40 best-corrected visual acuity or better.
256 th factor without significant improvement of best-corrected visual acuity or macular edema.
257  differences in the postoperative unaided or best-corrected visual acuity, or in the numbers of patie
258 nd 52 weeks, having excluded fluctuations in best corrected visual acuity owing to vitreous haemorrha
259 ), significantly worse visual functions were best-corrected visual acuity (P = 0.0444), low-luminance
260 ns, cycloplegic refractions, uncorrected and best-corrected visual acuities, power vector of astigmat
261 ensity in the SRL negatively correlated with best-corrected visual acuity (r = -0.28; P = .05) and se
262 reoperative and postoperative data including best corrected visual acuity recorded in LogMAR units, s
263                                              Best-corrected visual acuity recorded before surgery ran
264                                              Best-corrected visual acuity remained stable in both gro
265 -related macular degeneration and a baseline best-corrected visual acuity score of 20/100 or less in
266 prehensive ophthalmic examination, including best-corrected visual acuity, slit-lamp biomicroscopy, a
267                                              Best-corrected visual acuity, slit-lamp biomicroscopy, d
268 amination, including medical history review, best-corrected visual acuity, slitlamp biomicroscopy, in
269                          Ophthalmic history, best-corrected visual acuity, spectral-domain OCT result
270               Ophthalmic assessment included best-corrected visual acuity testing, electrophysiologic
271 improved from a mean (SD) of 2.5 (1.6) using best-corrected visual acuity to 9.5 (0.5) using the port
272 d RIDE/RISE, the proportion of patients with best-corrected visual acuity typically required for an u
273                     We assessed preoperative best-corrected visual acuity; ultrasound central corneal
274     All patients routinely underwent Snellen best-corrected visual acuity (VA) measurement, CFP, spec
275                       The mean +/- SD of the best-corrected visual acuity (VA) was 0.960 +/- 0.086 de
276                                              Best-corrected visual acuity (VA), complications, resolu
277 ristics of the RRD, surgical procedures, and best-corrected visual acuity (VA).
278 atment of Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (VA).
279                   Vision tests probed cones (best-corrected visual acuity [VA], contrast sensitivity)
280                                              Best-corrected visual acuity, visual fields, and OCT ret
281                                       Median best-corrected visual acuity was 0.20 logarithm of the m
282                                         Mean best-corrected visual acuity was 0.74 +/- 0.39 logarithm
283                            Upon examination, best-corrected visual acuity was 20/100 in the right eye
284                              On examination, best-corrected visual acuity was 20/20 in both eyes.
285                                              Best-corrected visual acuity was 20/50 or worse in 37.3%
286 r most GSS and NEI-VFQ-25 items, while lower best-corrected visual acuity was associated with lower s
287                       One-year postoperative best-corrected visual acuity was comparable (P = 0.09).
288 entage of patients achieving 20/40 or better best-corrected visual acuity was higher in the DMEK grou
289                                              Best-corrected visual acuity was improved in 13 eyes (81
290                                              Best-corrected visual acuity was measured using the Earl
291                                              Best-corrected visual acuity was severely reduced to res
292                                 Preoperative best-corrected visual acuity was significantly better in
293 over the entire follow-up period (P < .001); best-corrected visual acuity was similar at every time p
294 cted Visual Acuity (BW-BCVA), White on Black Best Corrected Visual Acuity (WB-BCVA), Mars Contrast Se
295 accommodation amplitude, pupil diameter, and best-corrected visual acuity were measured at baseline,
296  At 1 year, >/=10- and >/=15-letter gains in best-corrected visual acuity were observed in 34.5% (10/
297 change in vitreous haze grade, and change in best corrected visual acuity) were significantly better
298 s' functionality in 3 scenarios: using their best-corrected visual acuity with no low-vision aids, us
299                                   Changes in best-corrected visual acuity with RTH258 were comparable
300         The prevalence of visual impairment (best-corrected visual acuity worse than 20/40 in the bet

 
Page Top